RU2548817C2 - БЛОКИРУЮЩИЕ АНТИТЕЛА ПРОТИВ Dkk-1 И ИХ ПРИМЕНЕНИЯ - Google Patents

БЛОКИРУЮЩИЕ АНТИТЕЛА ПРОТИВ Dkk-1 И ИХ ПРИМЕНЕНИЯ Download PDF

Info

Publication number
RU2548817C2
RU2548817C2 RU2011145435/10A RU2011145435A RU2548817C2 RU 2548817 C2 RU2548817 C2 RU 2548817C2 RU 2011145435/10 A RU2011145435/10 A RU 2011145435/10A RU 2011145435 A RU2011145435 A RU 2011145435A RU 2548817 C2 RU2548817 C2 RU 2548817C2
Authority
RU
Russia
Prior art keywords
antibody
antibodies
amino acid
seq
dkk
Prior art date
Application number
RU2011145435/10A
Other languages
English (en)
Russian (ru)
Other versions
RU2011145435A (ru
Inventor
Мей ЛИ
Вишвас Мадхав ПАРАЛКАР
Джоуми ПОНС
Донна Мари СТОУН
Original Assignee
Пфайзер Инк.
Ринат Ньюросайенс Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Пфайзер Инк., Ринат Ньюросайенс Корпорейшн filed Critical Пфайзер Инк.
Publication of RU2011145435A publication Critical patent/RU2011145435A/ru
Application granted granted Critical
Publication of RU2548817C2 publication Critical patent/RU2548817C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
RU2011145435/10A 2009-05-12 2010-05-10 БЛОКИРУЮЩИЕ АНТИТЕЛА ПРОТИВ Dkk-1 И ИХ ПРИМЕНЕНИЯ RU2548817C2 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US17765009P 2009-05-12 2009-05-12
US61/177,650 2009-05-12
US24463809P 2009-09-22 2009-09-22
US61/244,638 2009-09-22
PCT/IB2010/052056 WO2010131185A1 (en) 2009-05-12 2010-05-10 Blocking anti-dkk-1 antibodies and their uses

Publications (2)

Publication Number Publication Date
RU2011145435A RU2011145435A (ru) 2013-06-20
RU2548817C2 true RU2548817C2 (ru) 2015-04-20

Family

ID=42315893

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2011145435/10A RU2548817C2 (ru) 2009-05-12 2010-05-10 БЛОКИРУЮЩИЕ АНТИТЕЛА ПРОТИВ Dkk-1 И ИХ ПРИМЕНЕНИЯ

Country Status (20)

Country Link
US (2) US8338576B2 (enExample)
EP (1) EP2430048A1 (enExample)
JP (1) JP2012526542A (enExample)
KR (1) KR101471239B1 (enExample)
CN (1) CN102666584A (enExample)
AR (1) AR076668A1 (enExample)
AU (1) AU2010246981B2 (enExample)
BR (1) BRPI1010540A2 (enExample)
CA (1) CA2761696A1 (enExample)
CO (1) CO6460768A2 (enExample)
IL (1) IL216304A0 (enExample)
MX (1) MX2011012039A (enExample)
NZ (1) NZ596274A (enExample)
PE (1) PE20120475A1 (enExample)
RU (1) RU2548817C2 (enExample)
SA (1) SA110310369B1 (enExample)
SG (1) SG175881A1 (enExample)
TW (1) TWI411444B (enExample)
WO (1) WO2010131185A1 (enExample)
ZA (1) ZA201108310B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12630651B2 (en) 2020-09-28 2026-05-19 Angitia Incorporated Limited Anti-sclerostin constructs and uses thereof
RU2863566C2 (ru) * 2020-09-28 2026-06-05 Ангиция Инкорпорейтед Лимитед Антитело к склеростину или его связывающий склеростин фрагмент (варианты), биспецифическое антитело или его биспецифический антигенсвязывающий фрагмент (варианты), фармацевтическая композиция и способ лечения или предупреждения нарушения, связанного с костью, и их применение в изготовлении лекарственного препарата для указанного лечения или предупреждения

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101925611A (zh) * 2007-11-21 2010-12-22 安姆根有限公司 Wise结合剂和表位
EP3838922A1 (en) * 2010-10-27 2021-06-23 Amgen Inc. Dkk1 antibodies and methods of use
US20120189633A1 (en) 2011-01-26 2012-07-26 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies and uses thereof
WO2012154983A2 (en) 2011-05-10 2012-11-15 Biocare Medical, Llc Systems and methods for anti-pax8 antibodies
US10316103B1 (en) 2012-03-30 2019-06-11 Biocare Medical, Llc Systems and methods for anti-Uroplakin III antibodies
EP4063391A1 (en) * 2012-07-25 2022-09-28 Celldex Therapeutics, Inc. Anti-kit antibodies and uses thereof
ES2682345T3 (es) 2012-09-27 2018-09-20 Biocare Medical, Llc Sistemas y procedimientos de anticuerpos antiuroplaquina II
WO2014100220A2 (en) 2012-12-18 2014-06-26 Biocare Medical, Llc Antibody cocktail systems and methods for classification of histologic subtypes in lung cancer
DK2962113T3 (da) 2013-02-28 2019-07-01 Biocare Medical Llc Systemer og fremgangsmåder med anti-p40-antistoffer
GB201312638D0 (en) * 2013-07-15 2013-08-28 King S College London Biomarkers
US9816997B2 (en) 2013-10-03 2017-11-14 Biocare Medical, Llc Anti-SOX10 antibody systems and methods
JP6768639B2 (ja) 2014-05-23 2020-10-21 セルデックス セラピューティクス，インコーポレーテッド 好酸球又はマスト細胞関連障害の治療
CN107750254B (zh) 2015-05-18 2021-08-20 伊莱利利公司 抗Dkk-1-抗RANKL双特异性抗体化合物
EP4640703A3 (en) * 2017-11-14 2026-04-08 Chugai Seiyaku Kabushiki Kaisha Anti-c1s antibodies and methods of use
EP3787645A4 (en) * 2018-05-02 2022-06-01 Ortheus, Inc. SYSTEMS AND METHODS FOR LOCAL MODULATION OF WNT SIGNALING
CA3137649A1 (en) 2019-05-15 2020-11-19 Chugai Seiyaku Kabushiki Kaisha An antigen-binding molecule, a pharmaceutical composition, and a method
CN112180094A (zh) * 2019-07-04 2021-01-05 上海东慈生物科技有限公司 Dkk1抑制剂在预防和/或治疗肿瘤恶病质与糖尿病伴随疾病中的应用
KR102192471B1 (ko) * 2019-10-18 2020-12-17 주식회사 인코스팜 탈모 완화 및 모발 성장을 촉진시키는 펩타이드 및 이를 포함하는 화장료 조성물
KR102494042B1 (ko) 2020-11-20 2023-02-07 주식회사 하울바이오 인간모유두세포의 성장을 촉진하는 항-dkk-1 항체 및 이의 용도
CN112592402B (zh) * 2020-12-02 2022-04-26 杭州奕安济世生物药业有限公司 抗dkk2抗体、包含该抗dkk2抗体的组合物及其用途

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7057017B2 (en) 1997-04-16 2006-06-06 Millennium Pharmaceuticals, Inc. Human dickkopf-related protein and nucleic acid molecules and uses therefor
US6391311B1 (en) 1998-03-17 2002-05-21 Genentech, Inc. Polypeptides having homology to vascular endothelial cell growth factor and bone morphogenetic protein 1
DE19747418C1 (de) 1997-10-27 1999-07-15 Deutsches Krebsforsch Inhibitor-Protein des wnt-Signalwegs
US7446181B2 (en) 1998-01-15 2008-11-04 Millennium Pharmaceuticals, Inc. Antibodies that bind human Dickkopf-1 proteins
ES2312205T3 (es) 1998-03-10 2009-02-16 Genentech, Inc. Nuevo polipeptido y acidos nucleicos que lo codifican.
US6962797B2 (en) 1998-04-15 2005-11-08 Genentech, Inc. Nucleic acids encoding PRO615
US6344541B1 (en) 1998-09-25 2002-02-05 Amgen Inc. DKR polypeptides
US20030203446A1 (en) 1998-10-07 2003-10-30 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6673549B1 (en) 2000-10-12 2004-01-06 Incyte Corporation Genes expressed in C3A liver cell cultures treated with steroids
HUP0303194A2 (hu) * 2001-02-16 2003-12-29 Genentech, Inc. DKK-1 és antagonistái alkalmazásai
US20040038860A1 (en) 2002-05-17 2004-02-26 Allen Kristina M. Reagents and methods for modulating dkk-mediated interactions
EP1395285A4 (en) * 2001-05-17 2005-06-01 Genome Therapeutics Corp REAGENTS AND METHODS FOR MODULATING DKK-MEDIATED INTERACTIONS
US7308364B2 (en) 2001-11-07 2007-12-11 The University Of Arkansas For Medical Sciences Diagnosis of multiple myeloma on gene expression profiling
JP2005512557A (ja) 2001-11-07 2005-05-12 ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティー オブ アーカンソー 遺伝子発現プロファイリングに基づく多発性骨髄腫の診断、予後、および治療標的候補の同定
US7371736B2 (en) 2001-11-07 2008-05-13 The Board Of Trustees Of The University Of Arkansas Gene expression profiling based identification of DKK1 as a potential therapeutic targets for controlling bone loss
US7894992B2 (en) 2001-11-07 2011-02-22 Board Of Trustees Of The University Of Arkansas Diagnosis and classification of multiple myeloma
MXPA05006033A (es) 2002-12-05 2006-03-08 Univ Arkansas Determinantes moleculares de enfermedad osea por mieloma, y usos de los mismos.
US7811750B2 (en) 2002-12-05 2010-10-12 Board Of Trustees Of The University Of Arkansas Molecular determinants of myeloma bone disease and use thereof
US7642238B2 (en) 2002-12-05 2010-01-05 Shaughnessy John D Molecular determinants of myeloma bone disease and uses thereof
US8124087B2 (en) 2002-12-05 2012-02-28 Board Of Trustees Of The University Of Arkansas Methods of controlling bone loss by inhibiting DKK1
US20050084494A1 (en) 2003-05-21 2005-04-21 Darwin Prockop Inhibitors of Dkk-1
US8637506B2 (en) 2003-09-22 2014-01-28 Enzo Biochem, Inc. Compositions and methods for bone formation and remodeling
US8343922B2 (en) 2004-05-19 2013-01-01 Enzo Biochem, Inc. Compositions and methods for the stimulation or enhancement of bone formation and the self-renewal of cells
ES2414460T3 (es) 2004-08-04 2013-07-19 Amgen Inc. Anticuerpos para Dkk-1
AR060017A1 (es) * 2006-01-13 2008-05-21 Novartis Ag Composiciones y metodos de uso para anticuerpos de dickkopf -1
WO2008070112A1 (en) 2006-12-06 2008-06-12 The Board Of Trustees Of The University Of Arkansas Overexpression of wnt ligands and treatment of lytic bone diseases
CN101641373B (zh) * 2007-02-08 2015-02-11 默沙东公司 Dkk-1的特异性抗体
AR075989A1 (es) 2009-04-10 2011-05-11 Lilly Co Eli Anticuerpo dkk -1 (dickkopf-1) humano disenado por ingenieria

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
А2, 26.07.2007. O. AGUILERA, et al., "Epigenetic inactivation of the Wnt antagonist DICKKOPF-1 (DKK-1) gene in human colorectal cancer", Oncogene (2006) 25, pp. 4116-4121. Н.М. ШУБА "Остеопороз - актуальная проблема XXI века: современное представление о патогенезе и терапии", Украхнський ревматологiчний журнал, N 2 (32), 2008, стр. 5-14. М. БОРСЕТБ и др. "Роль фактора роста гепатоцитов (HGF) в патогенезе множественной миеломы", Клеточная терапия и трансплантация, том 1, номер 1, 23 мая 2008, c. 60-61, doi: 10.3205/ctt2008-05-23-001-ru-a *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12630651B2 (en) 2020-09-28 2026-05-19 Angitia Incorporated Limited Anti-sclerostin constructs and uses thereof
RU2863566C2 (ru) * 2020-09-28 2026-06-05 Ангиция Инкорпорейтед Лимитед Антитело к склеростину или его связывающий склеростин фрагмент (варианты), биспецифическое антитело или его биспецифический антигенсвязывающий фрагмент (варианты), фармацевтическая композиция и способ лечения или предупреждения нарушения, связанного с костью, и их применение в изготовлении лекарственного препарата для указанного лечения или предупреждения

Also Published As

Publication number Publication date
KR20120007078A (ko) 2012-01-19
SA110310369B1 (ar) 2014-09-02
SG175881A1 (en) 2011-12-29
TWI411444B (zh) 2013-10-11
ZA201108310B (en) 2013-04-24
US20130071921A1 (en) 2013-03-21
US20100291076A1 (en) 2010-11-18
BRPI1010540A2 (pt) 2016-03-15
EP2430048A1 (en) 2012-03-21
CO6460768A2 (es) 2012-06-15
PE20120475A1 (es) 2012-05-05
US8338576B2 (en) 2012-12-25
JP2012526542A (ja) 2012-11-01
TW201043247A (en) 2010-12-16
AR076668A1 (es) 2011-06-29
NZ596274A (en) 2013-11-29
RU2011145435A (ru) 2013-06-20
MX2011012039A (es) 2011-12-14
KR101471239B1 (ko) 2014-12-09
CA2761696A1 (en) 2010-11-18
IL216304A0 (en) 2012-01-31
US8586721B2 (en) 2013-11-19
AU2010246981A1 (en) 2011-12-08
WO2010131185A1 (en) 2010-11-18
AU2010246981B2 (en) 2013-12-19
CN102666584A (zh) 2012-09-12

Similar Documents

Publication Publication Date Title
US8338576B2 (en) Antibodies specific for DKK-1 and their uses
JP7023908B2 (ja) ヒトｉｌ－２３抗原結合タンパク質
US8101184B2 (en) Treatment methods using Dkk-1 antibodies
EP3612218B1 (en) Trem2 antigen binding proteins and uses thereof
EP2074149B1 (en) Compositions and methods relating to glucagon receptor antibodies
US7867493B2 (en) PRLR-specific antibody and uses thereof
WO2007109749A2 (en) Methods for preventing and treating amyloidogenic diseases
HK1175791A (en) Blocking anti-dkk-1 antibodies and their uses
HK40025990B (en) Trem2 antigen binding proteins and uses thereof
HK40025990A (en) Trem2 antigen binding proteins and uses thereof

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20160511